Cancer Genetics (CGIX) Trading Down 7.4%

Share on StockTwits

Cancer Genetics Inc (NASDAQ:CGIX) shares were down 7.4% during trading on Thursday . The company traded as low as $0.25 and last traded at $0.25. Approximately 874,498 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 2,606,691 shares. The stock had previously closed at $0.27.

Several research firms have issued reports on CGIX. ValuEngine upgraded Cancer Genetics from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Maxim Group reiterated a “hold” rating on shares of Cancer Genetics in a research note on Tuesday, November 20th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Cancer Genetics presently has a consensus rating of “Hold” and a consensus price target of $4.50.

The company has a quick ratio of 0.46, a current ratio of 0.46 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $6.93 million, a PE ratio of -0.32 and a beta of 1.18.

In related news, CEO John A. Roberts acquired 185,436 shares of the company’s stock in a transaction on Thursday, January 31st. The stock was purchased at an average cost of $0.23 per share, for a total transaction of $42,650.28. Following the completion of the purchase, the chief executive officer now directly owns 297,636 shares of the company’s stock, valued at approximately $68,456.28. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director John Pappajohn acquired 1,000,000 shares of the company’s stock in a transaction on Monday, January 14th. The shares were bought at an average price of $0.23 per share, with a total value of $230,000.00. Following the completion of the purchase, the director now directly owns 3,781,204 shares of the company’s stock, valued at $869,676.92. The disclosure for this purchase can be found here. Insiders have acquired 2,435,436 shares of company stock valued at $560,150 over the last quarter. Corporate insiders own 21.30% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its stake in Cancer Genetics by 106.6% during the fourth quarter. Geode Capital Management LLC now owns 221,803 shares of the medical research company’s stock worth $53,000 after acquiring an additional 114,448 shares in the last quarter. Renaissance Technologies LLC raised its stake in Cancer Genetics by 22.0% during the second quarter. Renaissance Technologies LLC now owns 587,300 shares of the medical research company’s stock worth $523,000 after acquiring an additional 105,900 shares in the last quarter. Vanguard Group Inc raised its stake in Cancer Genetics by 119.8% during the third quarter. Vanguard Group Inc now owns 532,426 shares of the medical research company’s stock worth $554,000 after acquiring an additional 290,146 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Cancer Genetics by 119.8% during the third quarter. Vanguard Group Inc. now owns 532,426 shares of the medical research company’s stock worth $554,000 after acquiring an additional 290,146 shares in the last quarter. Hedge funds and other institutional investors own 11.46% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Cancer Genetics (CGIX) Trading Down 7.4%” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/4204844/cancer-genetics-cgix-trading-down-7-4.html.

Cancer Genetics Company Profile (NASDAQ:CGIX)

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Read More: How Investors Can Profit from Options Trading

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

6,500 Shares in iShares Edge MSCI Min Vol EAFE ETF  Purchased by Ashford Capital Management Inc.
6,500 Shares in iShares Edge MSCI Min Vol EAFE ETF Purchased by Ashford Capital Management Inc.
B. Riley Wealth Management Inc. Has $5.79 Million Position in Vanguard Real Estate ETF
B. Riley Wealth Management Inc. Has $5.79 Million Position in Vanguard Real Estate ETF
SPDR S&P 500 ETF Trust  Holdings Lifted by Arthur M. Cohen & Associates LLC
SPDR S&P 500 ETF Trust Holdings Lifted by Arthur M. Cohen & Associates LLC
Ayalon Holdings Ltd. Has $1.38 Million Holdings in Visa Inc
Ayalon Holdings Ltd. Has $1.38 Million Holdings in Visa Inc
Acacia Communications, Inc.  VP Sells $1,215,480.00 in Stock
Acacia Communications, Inc. VP Sells $1,215,480.00 in Stock
Insider Selling: Aaron’s, Inc.  CEO Sells 45,000 Shares of Stock
Insider Selling: Aaron’s, Inc. CEO Sells 45,000 Shares of Stock


© 2006-2019 Ticker Report